Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Tuesday interim Phase 1 readout for INO-4800, its DNA vaccine candidate against the novel coronavirus.The Inovio Analyst: Piper Sandler analyst Christopher Raymond maintained a Neutral rating and $8 price target for Inovio.The Inovio Thesis: There wasn’t a ton of detail at this point from the readout except that 94% or 34 of the 36 patients, demonstrating an “overall immunological” response at week 6, with a benign safety profile, Raymond said in a note. This appeared consistent with preclinical data published in May.Raymond, however, said he would like to see data …read more
Source:: Yahoo Finance
